TAR — Tariff (miscellaneous tariff bills)
GENERAL DISCUSSIONS REGARDING SECTION 232 INVESTIGATION ON BIOPHARMACEUTICALS
Lobbyists:
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
1st Quarter - Report · 2026
- Filing UUID
5ff791c9-7687-4a66-807d-011eba5b3746- Type
Q1— 1st Quarter - Report- Period
- first_quarter
- Year
- 2026
- Posted
- 2026-04-20 23:04:43
- Income (reported)
- —
- Expenses (reported)
- $530,000
- Expenses method
- A
- Filing document
- Open on lda.senate.gov
Registrant (lobbying firm)
Develops and commercializes biopharmaceuticals.
- Contact
- JASON KAUNE
- Phone
- +1 415-389-6800
- Address
- zip:94901, city:San Rafael, state:CA, street:770 Lindaro Street
Client
- State
- CA
- Country
- US
- Government-entity client
- false
- Effective date
- 2013-04-01
Issues lobbied + lobbyists (3)
HCR — Health Issues
GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT
Lobbyists:
Government entities lobbied: Commerce, Dept of (DOC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
MMM — Medicare/Medicaid
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION
Lobbyists:
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE